In this monthly Industry Insights on Research and Innovation Seminar (IIRIS) series, presented by Technology Opportunities & Ventures (TOV), experts from innovative startups will join us to discuss how their companies are using cutting-edge science to develop the next generation of therapeutics, diagnostics, medical devices, and more. They will also share insights into industry trends and career opportunities, and answer questions from attendees. The events are free and open to the NYU community and a boxed lunch is provided.

September's guest speaker is Dr. Archis Bagati, Founder and CEO of Pyrojas. Pyrojas is focused on using a personalized and data-driven approach to developing immunotherapies that harness the power of the immune system to recognize and destroy cancer cells. Their technology enables the creation of immunotherapies that are tailored to the unique genetic makeup of each patient's tumor, providing a precise and targeted approach to cancer treatment. Grounded in a commitment to excellence, innovation, and patient-centricity, Pyrojas is dedicated to promoting durable immunity and recurrence-free survival of patients from cancer.

Full speaker bio:

Dr. Archis Bagati, a distinguished cancer immunologist and Founder and CEO of Pyrojas Corporation, is at the forefront of developing personalized cancer vaccines targeting solid tumors. With over 12 years of deep expertise in molecular and cellular immunology, oncology, gene editing, and personalized genomics, Dr. Bagati is a leader in cancer research and therapy innovation.

A former faculty member at Harvard Medical School, Dr. Bagati’s academic foundation includes dual bachelor’s degrees in Pharmacology and Toxicology, and Biotechnology, followed by a master’s degree in Pharmacology and Toxicology. He earned his Ph.D. in Molecular and Cellular Biophysics and Biochemistry at Roswell Park Cancer Institute, where he made significant strides in unraveling the mechanisms of cancer therapy response and resistance. His postdoctoral work at Dana-Farber Cancer Institute and Harvard further sharpened his focus on tumor immunology, where he developed novel antibodies for breast cancer and uncovered critical immune evasion strategies used by tumors.

At Pyrojas Corporation, Dr. Bagati leads an elite team of scientists and clinicians, driving the development of patient-specific immunotherapies. His innovative technology platform is pioneering the creation of personalized vaccines and T cell therapies, with the goal of achieving long-term, relapse-free survival for patients.

Dr. Bagati’s work has been widely recognized through numerous high-impact publications and his role as a driving force in the development of transformative cancer therapies. His unwavering commitment to scientific excellence and patient-centered care continues to push the boundaries of cancer treatment.